Jeito Capital announces significant participation in $187 million Series A financing for Callio Therapeutics to advance innovative multi-payload ADC programs designed to maximize therapeutic benefit for cancer patients
Callio Therapeutics is a biotechnology company developing multi-payload ADCs with technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience
Investment will contribute to achieve clinical proof-of-concept for
Callio's HER-2-targeted dual-payload ADC and a second undisclosed ADC program
Jeito's investment reinforces its commitment to cutting-edge oncology innovations addressing treatment resistance and improving patient outcomes
Paris, March 3rd 2025 – Jeito Capital ('Jeito'), a global leading independent Private Equity fund dedicated to biopharma, announced today its significant participation in the $187 million (€180.2 million1) Series A financing round in Callio Therapeutics ('Callio'), a newly launched biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy.
Callio Therapeutics was founded by Frazier Life Sciences to develop next-generation multi-payload antibody-drug conjugates (ADCs) based on technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience. The company is led by co-founder and CEO Piers Ingram, PhD, alongside a founding management team with deep expertise in ADC development bringing experience from leading biotechnology and biopharmaceutical companies (including Hummingbird Bioscience, ProfoundBio, Silverback Therapeutics, SeaGen, Medarex, and Genentech).
The $187 million Series A financing was led by Frazier Life Sciences with significant participation from Jeito alongside an investment syndicate including Novo Holdings A/S Omega Funds, ClavystBio, Platanus, Norwest, Pureos Bioventures, SEEDS Capital and EDBI. The strength of this syndicate underscores the broad confidence in Callio's innovative ADC platform and its potential to reshape cancer therapy.
Callio Therapeutics will use the proceeds from the Series A financing to achieve clinical proof-of-concept for its HER2-targeted dual-payload ADC and a second undisclosed ADC program, all designed to maximize therapeutic benefit for cancer patients by overcoming the limitations of single-payload therapies. By enabling the targeted delivery of rational drug combinations to tumor cells, Callio's approach has the potential to significantly enhance efficacy and address resistance mechanisms.
Rachel Mears, Partner at Jeito will join Callio's Board of Director as Board member.
Through this investment, Jeito reinforces its commitment to supporting transformative oncology innovations that address key resistance mechanisms in cancer treatment. Callio's differentiated multi-payload ADC platform aligns with Jeito's investment thesis of backing high-potential biopharma companies developing next-generation therapies with the potential for global leadership.
Dr Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito Capital said: ' We are pleased to support Callio Therapeutics as it advances its differentiated multi-payload ADC platform to address some of the biggest challenges in oncology. As long-standing investors in this therapeutic area, we recognize the quality and potential of Callio's approach to overcome resistance mechanisms and improve outcomes for patients with hard-to-treat cancers. At Jeito, we believe that strategic collaboration and bold innovation are key to accelerating the next generation of targeted therapies, and we look forward to working alongside the Callio team to bring these advances to patients in need. '
Rachel Mears, Parner at Jeito Capital added: ' Callio is a highly innovative company that benefits from an experienced management team and deep expertise in oncology, where new therapies remain highly needed for those suffering from various forms of cancer. We look forward to collaborating with Callio's team through our collective knowledge and expertise in both ADC and oncology with the ambition to go faster to patients with high unmet needs. '
Piers Ingram, PhD, co-founder and Chief Executive Officer of Callio Therapeutics concluded: ' We are delighted to be launching Callio Therapeutics with this very strong syndicate of investors. Multi-payload ADCs have the potential to enable the targeted delivery of rational drug combinations to cancer cells, and may provide significantly enhanced efficacy. This new generation of ADC therapies may meaningfully improve outcomes for patients.'
About Jeito Capital
Jeito Capital is a global leading Private Equity fund with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients' access globally, especially in Europe and the United States. Jeito Capital has €534 million under management and a rapidly growing portfolio of investments. Jeito Capital is based in Paris with a presence in Europe and the United States.
For more information, please visit www.jeito.life or follow us on LinkedIn or X.
About Callio Therapeutics
Headquartered in Seattle and Singapore, Callio Therapeutics is focused on realizing the promise of multi-payload antibody-drug conjugates to transform cancer patient outcomes. The company is developing next-generation, multi-payload antibody-drug conjugates (ADCs) that feature differentiated payload and linker technologies that enable targeted delivery of multi agents to tumor cells to maximize therapeutic benefit. Callio Therapeutics' lead program is a HER2-targeted dual-payload ADC. Callio Therapeutics was created by Frazier Life Sciences, a longstanding investment firm focused on innovative therapeutics, based on ADC technology and programs exclusively in-licensed from Hummingbird Bioscience. For more information , please visit www.calliotx.com and follow Callio Therapeutics on LinkedIn.
Contacts:
Jeito Capital
Rafaèle Tordjman, Founder & CEO
Jessica Fadel, EA
Tel: +33 6 33 44 25 47
Maior
Stéphanie Elbaz – Tel: +33 6 46 05 08 07
ICR Healthcare
Mary-Jane Elliott / Davide Salvi / Kris Lam
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Marriott to launch three new hotels in Canada by 2030
Marriott International has revealed plans to introduce three new hotels in Calgary, Canada, as part of a mixed-use development in the city's Culture + Entertainment District. The W, JW Marriott, and an Autograph Collection hotels are scheduled to open at Stampede Park in 2028, 2029, and 2030, respectively. The developments will be spearheaded by Calgary-based joint-venture partners Truman and Louson. The W and JW Marriott properties are expected to be among the tallest residential towers in Western Canada. Truman's chief operating officer Tony Trutina said: "As a Calgary-based and family-owned company, we have a deep commitment to this city, and we believe this project will be a significant catalyst for the local economy. 'Beyond creating numerous construction jobs, these hotels are expected to generate substantial long-term employment opportunities, boost tourism, and support local businesses through increased visitor spending." Soaring at 69 storeys, the W Calgary tower is designed to include 157 guest rooms, 27 suites, and 239 branded residences. The property will feature a 7,500ft² Spa, a speciality restaurant, 16,259ft² of meeting space, a FIT studio, and a rooftop bar. Residents will have access to exclusive facilities and a private entrance. The JW Marriott hotel will stand at 62 storeys, featuring 248 guest rooms and 120 branded residences. Amenities will include 32,500ft² of meeting space, indoor and outdoor pools, a JW Market, a JW Garden, a retail area, and additional facilities. These announcements build on Truman's recent collaboration with Calgary Stampede to create a 320-key hotel operating under the Autograph Collection Hotels brand. This full-service property will offer 320 guest rooms, 15,000ft² of meeting and event space, and 14,000ft² of food and beverage options, including multiple restaurants, a lobby bar, and a rooftop lounge. A name for this hotel will be unveiled later this year. Marriott International Canada chief operating officer Paul Cahill said: 'We are thrilled to closely collaborate with Truman and Louson, whose combined passion and love for Calgary will be a perfect complement to the elevated service that guests have come to expect from the Marriott Bonvoy portfolio.' These projects will provide a total of more than 700 premium and luxury hotel rooms and nearly 360 branded residences. This development meets the growing demand for accommodations near venues such as the BMO Centre and the upcoming Scotia Place event centre. With a combined investment of C$1.47bn ($1.1bn) from Truman and Louson, these projects are expected to support more than 9,100 jobs while under construction and create over 2,000 ongoing positions in operations and tourism. Earlier this year, Marriott International broadened its Canadian portfolio with the launch of Muir, a Luxury Collection Hotel in Halifax. "Marriott to launch three new hotels in Canada by 2030" was originally created and published by Hotel Management Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
The 16% return this week takes Koh Brothers Group's (SGX:K75) shareholders one-year gains to 68%
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But if you pick the right individual stocks, you could make more than that. For example, the Koh Brothers Group Limited (SGX:K75) share price is up 68% in the last 1 year, clearly besting the market return of around 16% (not including dividends). If it can keep that out-performance up over the long term, investors will do very well! Looking back further, the stock price is 37% higher than it was three years ago. After a strong gain in the past week, it's worth seeing if longer term returns have been driven by improving fundamentals. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Koh Brothers Group wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. Some companies are willing to postpone profitability to grow revenue faster, but in that case one would hope for good top-line growth to make up for the lack of earnings. Koh Brothers Group actually shrunk its revenue over the last year, with a reduction of 33%. The stock is up 68% in that time, a fine performance given the revenue drop. To us that means that there isn't a lot of correlation between the past revenue performance and the share price, but a closer look at analyst forecasts and the bottom line may well explain a lot. The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail). You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic. It's nice to see that Koh Brothers Group shareholders have received a total shareholder return of 68% over the last year. Since the one-year TSR is better than the five-year TSR (the latter coming in at 6% per year), it would seem that the stock's performance has improved in recent times. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. It's always interesting to track share price performance over the longer term. But to understand Koh Brothers Group better, we need to consider many other factors. To that end, you should learn about the 2 warning signs we've spotted with Koh Brothers Group (including 1 which shouldn't be ignored) . Of course Koh Brothers Group may not be the best stock to buy. So you may wish to see this free collection of growth stocks. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Singaporean exchanges. — Investing narratives with Fair Values Suncorp's Next Chapter: Insurance-Only and Ready to Grow By Robbo – Community Contributor Fair Value Estimated: A$22.83 · 0.1% Overvalued Thyssenkrupp Nucera Will Achieve Double-Digit Profits by 2030 Boosted by Hydrogen Growth By Chris1 – Community Contributor Fair Value Estimated: €14.40 · 0.3% Overvalued Tesla's Nvidia Moment – The AI & Robotics Inflection Point By BlackGoat – Community Contributor Fair Value Estimated: $384.84 · 0.2% Overvalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Global experts at SMU City Dialogues Vienna: Urban resilience requires trust, equity and 'smart enough' solutions
SINGAPORE and VIENNA, July 4, 2025 /PRNewswire/ -- As a partner event of the Mayors Forum of the World Cities Summit 2025, the fourth edition of SMU City Dialogues was successfully organised by Singapore Management University (SMU) in partnership with Urban Innovation Vienna (UIV) on 2 July 2025 at Vienna City Hall. City Dialogues Vienna welcomed over 100 attendees from 20 countries; with representation from more than 20 universities and over 30 private and public organisations – a testament to the diversity and dynamism of our global community, and the urgency and relevance of the dialogue topic of urban resilience. The event opened with a welcome address by SMU Provost, Professor Alan Chan, followed by remarks from Mr Melvyn Ong, Permanent Secretary (Development) at the Ministry of National Development, Republic of Singapore. The keynote address was delivered by Mr Jürgen Czernohorszky, Executive City Councillor for Climate, Environment, Democracy and Personnel of the City of Vienna. Centered around the guiding question "What is the value of urban resilience?", the event brought together urban leaders, policymakers and academics from Europe, Asia and beyond to exchange actionable insights towards resilient, inclusive and future-ready cities. The programme featured three thematic tracks, each addressing a core dimension of urban resilience: Finance and Public-Private Partnerships Social Equity and Environmental Sustainability Innovation and Technology These parallel discussions concluded with a joint key takeaway session led by SMU professors Winston Chow and Orlando Woods, alongside UIV's Johannes Lutter. Their insights made one thing clear: urban resilience is not a buzzword, but a lived responsibility which requires trust, participation, and context-sensitive action. Professor Winston Chow, Co-Chair of the IPCC Working Group II and Professor of Urban Climate at SMU, said, "Resilience isn't just about surviving, it's about thriving. We need to align financial systems with social goals, build trust through good governance, and empower communities to shape their own future." Prof Chow also cautioned against over-reliance on public-private partnerships, noting that "public-private partnerships can be powerful tools, but they are not universal solutions. They require competent, stable governments, extensive due diligence and clear alignment of interest." SMU Professor of Geography Orlando Woods, who is also Director of the SMU Urban Institute, reflected on the limitations of digital solutions in addressing complex urban challenges. While his group was tasked with exploring innovation and technology, much of the discussion shifted toward the structural problems that technology alone cannot resolve. "It's not about being a smart city. It's about being a smart enough city. Smart enough relative to the context, the specific problem we are trying to solve with the technology that we have." He emphasised that overreliance on data and digital tools often leads to oversimplified responses, while masking deeper systemic issues like inequality, mental health, or infrastructural neglect. Dr Johannes Lutter Senior Urban Planner at Urban Innovation Vienna, outlined three key messages on how resilience can be made more socially inclusive and locally grounded. "Given our limited resources, it is essential that we take targeted action—focusing in particular on those who are most vulnerable. To do so effectively, we must have a clear understanding of who is at risk." "We must restore agency to communities—not by shifting responsibility onto them and stepping back, but by fostering a structured dialogue between governments and communities, ensuring genuine collaboration between public institutions and the people they serve," he added. About SMU City Dialogues Initiated in 2019 by Singapore Management University, the City Dialogues series fosters candid exchange among policymakers, academics and business leaders. It aims to generate actionable recommendations for sustainable and inclusive urban development. Previous editions held in Singapore and Bangkok successfully brought together leaders from government, industry, and academia to engage in honest, action-oriented conversations. City Dialogues | City Perspectives View original content to download multimedia: SOURCE Singapore Management University Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
